About MDC1
No gene-level summary was recorded for this case.
No variant summary was recorded for this case.
Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.
Uncertain.The recorded classification is uncertain significance.
Gene-level background from the recorded interpretation.
Words with a dotted underline have a short definition. Hover or tap them.No gene-level summary was recorded for this case.
The recorded framework is Not recorded. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.
The applied criteria and their strengths are shown as assessed under the stated framework.
NM_014641.2:c.619_642del is a 24bp in-frame deletion removing 8 amino acids (p.Gly207_Phe214del), causing a protein length change. The deleted segment does not appear to be a simple tandem repeat region based on available sequence analysis. However, the functional significance of this specific 8-amino-acid deletion in a 2089-amino-acid protein is uncertain, warranting supporting rather than moderate strength.
SpliceAI predicts no splice impact for this variant (max delta score = 0.00 across all splice categories). Although this is expected for an in-frame exonic deletion and represents a single computational line of evidence, it is consistent with no splicing aberration. REVEL and BayesDel are not applicable to this variant type.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM4 supporting, BP4 supporting benign; combination = 1 supporting + 1 supporting benign, which maps to VUS.
Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.
gnomAD v4.1 allele counts were not recorded for this variant.
Absent from gnomAD v2.1.
Absent from gnomAD-Canada v1.0.
Recorded SpliceAI maximum delta score: 0.000. Refer to the recorded PP3/BP4 rationale for interpretation.
1 Benign. ClinVar API review status: criteria provided, single submitter.
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MDC1 is a regulator of the cell cycle response to DNA damage. It has tumor suppressor functions in the context of cancer.
This variant has previously been reported in somatic cancers (COSMIC; COSV64523420, n = 3 times).
This variant does not lie in a statistically significant hotspot.
ACMG/AMP criteria under Not recorded, with the data and sources behind each one.
29 criteria with recorded statuses: 2 met · 21 not met · 0 not assessed · 6 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.
NM_014641.2:c.619_642del (p.Gly207_Phe214del) is an in-frame deletion removing 8 amino acids in MDC1.
PM4 (supporting) is met: this is a 24bp in-frame deletion causing a protein length change. The deleted segment does not appear to lie within a repetitive region.
BP4 (supporting benign) is met: SpliceAI predicts no splice impact (max delta score = 0.00).
This variant does not meet PVS1, PS1–PS5, PM1–PM3, PM5–PM6, PP1–PP5, BA1, BS1–BS4, BP1–BP3, or BP5–BP7 due to absence of supporting evidence or inapplicability to this variant type.
ClinVar classifies this variant as Benign (1 clinical laboratory, single submitter), but the review status does not meet the 3-star expert panel threshold for BP6.
This variant has been observed in somatic cancers (COSMIC, n=3), but somatic occurrence does not independently establish germline pathogenicity.
Overall classification: Uncertain Significance (VUS). One supporting pathogenic criterion (PM4) is balanced by one supporting benign criterion (BP4), yielding conflicting evidence insufficient for a likely pathogenic or likely benign classification per generic ACMG/AMP 2015 rules.
No criteria match.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
No further detail was recorded.
Every interpreted variant in MDC1, mapped onto the exon structure of NM_014641.2. Select a row to find it on the plot.
| Protein | Location | Classification | Link |
|---|
Absent from gnomAD v4.1.
Absent from gnomAD v2.1.
Absent from gnomAD-Canada v1.0.
No further detail was recorded.
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).
0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.
Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.
The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.
Absent from gnomAD v4.1.
Absent from gnomAD v2.1.
Absent from gnomAD-Canada v1.0.
This variant has been reported in ClinVar as Benign (1 clinical laboratory). (ClinVarID = 2656343)
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MDC1 is a regulator of the cell cycle response to DNA damage. It has tumor suppressor functions in the context of cancer.
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV64523420, n = 3 times).
This variant does not lie in a statistically significant hotspot.